<DOC>
	<DOCNO>NCT02754882</DOCNO>
	<brief_summary>This study design establish biosimilarity SB8 , propose biosimilar product bevacizumab , EU-sourced bevacizumab , patient metastatic recurrent non-squamous non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>A Study Comparing SB8 Avastin® Patients With Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Standard efficacy parameter , safety profile , pharmacokinetics immunogenicity compare SB8 bevacizumab .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Aged ≥ 18 year 2 . ECOG performance status 01 3 . Histologicallyconfirmed metastatic recurrent nonsquamous nonsmall cell lung cancer 4 . At least one measurable lesion accord RECIST v1.1 . 5 . Able receive bevacizumab , carboplatin paclitaxel base adequate laboratory clinical parameter 1 . Diagnosis small cell carcinoma lung squamous cell carcinoma 2 . Sensitizing EGFR mutation ALK rearrangements 3 . Increased risk bleeding determine investigator base radiographic / clinical finding 4 . History systemic chemotherapy administer firstline set metastatic recurrent disease NSCLC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>avastin</keyword>
</DOC>